On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer.
This approval may enhance treatment options for patients with this specific cancer type, potentially impacting manufacturers and suppliers involved in the production of these therapies.
Source: fda.gov · Image: CANCER THERAPY PROGRAM CONTROL ROOM AND PATIENT TREATMENT AREA – NARA – 17420852 by Unknown authorUnknown author or not provided, Public domain, via Wikimedia Commons
Affordable access, full power:
For just $42 per month, the “Solo” plan unlocks the same API & FDF Intelligence data used by global companies.
You instantly see price ranges, dossiers, and certificates — and, most importantly, gain direct contacts to every manufacturer and FDF holder.
It’s a practical way to work with reliable data without heavy budgets.
Get started today with Solo access →
Get started today with Solo access →
